MRI for Pancreatic Cancer: Early Detection

What Is Pancreatic Cancer?

Pancreatic cancer is a malignancy arising from the cells of the pancreas — a 15cm organ sitting behind the stomach that produces digestive enzymes and hormones (insulin and glucagon). The most common type (about 85%) is pancreatic ductal adenocarcinoma (PDAC), originating from the cells lining the pancreatic ducts.

Pancreatic cancer has the lowest survival rate of any common cancer. In the UK, approximately 10,500 people are diagnosed each year, and the five-year survival rate remains under 10%. The reason for these stark numbers is that pancreatic cancer is typically silent in its early stages — by the time symptoms appear (jaundice, weight loss, new-onset diabetes, back pain), the cancer has often spread beyond the pancreas.

Only about 10-20% of patients are candidates for potentially curative surgery (Whipple procedure or distal pancreatectomy) at the time of diagnosis. Improving this figure through earlier detection is one of the most pressing challenges in oncology.

Risk factors include smoking (doubles the risk), chronic pancreatitis, new-onset diabetes after age 50, obesity, family history (5-10% of cases have a hereditary component), and certain genetic syndromes (BRCA2, Lynch syndrome, Peutz-Jeghers syndrome, familial atypical multiple mole melanoma syndrome).

Why MRI Is Used for Pancreatic Assessment

CT with contrast remains the primary staging tool for known pancreatic cancer. But MRI and MRCP (Magnetic Resonance Cholangiopancreatography) play specific, valuable roles:

• MRCP for duct assessment: MRCP uses heavily T2-weighted sequences to create non-invasive images of the pancreatic duct and bile ducts — equivalent to the information from ERCP (an invasive endoscopic procedure) but without the risks. It shows duct strictures, dilatation, stones, and communication with cystic lesions.
• Characterising pancreatic cystic lesions: MRI is superior to CT for characterising pancreatic cysts — which range from benign (serous cystadenoma) to premalignant (mucinous cystic neoplasm, IPMN) to malignant. MRI's soft tissue contrast shows internal features (septa, mural nodules, communication with the pancreatic duct) that guide management.
• Liver metastasis detection: MRI with liver-specific contrast agents (gadoxetic acid/Primovist) is more sensitive than CT for detecting small liver metastases — critical for staging and surgical planning.
• Screening high-risk individuals: For people with a strong family history or known genetic predisposition, annual or biannual MRI/MRCP (combined with endoscopic ultrasound) is the recommended surveillance strategy. No radiation exposure makes MRI ideal for repeated screening.
• Distinguishing cancer from pancreatitis: Chronic pancreatitis can cause a pancreatic mass that mimics cancer on CT. MRI with DWI and dynamic contrast enhancement provides additional tissue characterisation that can help (though biopsy is often still needed).

MRI Sequences Used

• Heavily T2-weighted MRCP sequences: Either 3D acquisitions (breathhold or respiratory-triggered) or thick-slab 2D images. Fluid in the bile and pancreatic ducts appears brilliant white against a dark background — providing a "road map" of the ductal anatomy without contrast injection.
• T2-weighted axial and coronal with fat saturation: Shows the pancreatic parenchyma and surrounding structures. Cystic lesions, duct dilatation, and peripancreatic fluid are well-visualised.
• T1-weighted axial with fat saturation (pre-contrast): Normal pancreatic parenchyma is bright on T1 fat-sat (higher than liver signal) due to its high protein content. A pancreatic mass typically appears dark relative to the normal parenchyma — this loss of normal T1 hyperintensity is one of the earliest MRI signs of pancreatic cancer.
• Dynamic contrast-enhanced T1 (arterial, venous, delayed phases): Pancreatic adenocarcinoma is typically hypovascular — it enhances less than the surrounding normal pancreas, particularly in the pancreatic/arterial phase. The relationship of the tumour to the superior mesenteric artery and vein, coeliac axis, and portal vein determines surgical resectability.
• DWI: Pancreatic cancer restricts diffusion (appearing bright on DWI, dark on ADC). DWI adds sensitivity for detecting small tumours and peritoneal deposits that might be missed on conventional sequences.
• Liver-specific contrast (gadoxetic acid): If liver metastasis detection is a priority, this contrast agent is taken up by normal hepatocytes (liver cells), making metastases stand out as dark areas against the bright enhanced liver parenchyma in the hepatobiliary phase (acquired 20 minutes after injection).

What Radiologists Look For

• Pancreatic mass: Size, location (head, neck, body, or tail), and signal characteristics. Most PDAC is hypo-enhancing relative to normal pancreas on the arterial phase.
• Double duct sign: Simultaneous dilatation of both the common bile duct and the main pancreatic duct, caused by a tumour in the pancreatic head obstructing both. This is a classic but not universal sign of pancreatic head cancer.
• Pancreatic duct changes: Abrupt duct cutoff (sudden termination of a dilated duct at the tumour margin), upstream duct dilatation, and parenchymal atrophy of the tail (due to chronic obstruction).
• Vascular involvement: The relationship of the tumour to the SMA, SMV, portal vein, coeliac axis, and hepatic artery determines resectability. Contact with or encasement of these vessels is precisely described using international consensus criteria (NCCN borderline resectable vs. locally advanced).
• Lymph node assessment: Enlarged or suspicious peripancreatic, coeliac, and para-aortic lymph nodes.
• Liver metastases: Even tiny (sub-centimetre) liver lesions can change management from surgery to palliative chemotherapy. MRI with DWI and liver-specific contrast is the most sensitive non-invasive method for detecting these.
• Peritoneal disease: DWI can detect tiny peritoneal implants that are invisible on CT.
• Cystic lesion characterisation: For incidentally discovered pancreatic cysts: communication with the main pancreatic duct (IPMN), septa (mucinous cystic neoplasm), mural nodules (potential malignancy), and size change over time — all follow-up criteria from international consensus guidelines (Fukuoka/European).

How to Prepare for the Scan

• Fast for 4-6 hours before the scan — an empty stomach reduces motion artefact from gastric peristalsis and improves gallbladder distension
• Some centres ask you to drink water or pineapple juice just before the scan to fill the stomach and duodenum, providing better contrast against the pancreas
• Continue essential medications (take them with a small sip of water)
• An anti-spasmodic injection (Buscopan/hyoscine butylbromide or glucagon) is usually given intravenously just before the scan to reduce bowel movement
• If contrast is being used, ensure the department has your recent kidney function blood tests (eGFR)

What Happens During the Scan

You'll lie on your back with a surface coil over your upper abdomen. The scan takes approximately 35-50 minutes for a full pancreatic protocol.

You'll need to hold your breath multiple times during the scan (typically 15-20 second breath-holds) — this is important because breathing moves the pancreas up and down, blurring the images. The radiographer will coach you through each breath-hold via the intercom.

If intravenous contrast is used, a cannula is placed before the scan. You may feel a brief warm sensation during the injection. For liver-specific contrast, a delayed set of images is acquired about 20 minutes after injection — you may be able to briefly sit up during this waiting period.

What MRI Can't Show

• Definitive tissue diagnosis: MRI can identify a suspicious mass and characterise it, but it cannot definitively confirm cancer. Tissue diagnosis requires biopsy — usually via EUS-guided fine needle aspiration (endoscopic ultrasound-guided biopsy).
• Very small tumours reliably: Even with optimal technique, PDAC under 10mm is difficult to detect on any imaging modality. This is why screening protocols for high-risk individuals combine MRI with endoscopic ultrasound (EUS), which has superior spatial resolution for small pancreatic lesions.
• Calcification: CT is superior for detecting pancreatic calcification (a feature of chronic pancreatitis). This is occasionally relevant for distinguishing chronic pancreatitis from cancer.
• Lung staging: A CT chest is still needed for complete staging — MRI of the abdomen doesn't assess the lungs adequately.

Treatment Pathways After Diagnosis

• Surgical resection: The only potentially curative treatment. Whipple procedure (pancreaticoduodenectomy) for head tumours, distal pancreatectomy for body/tail tumours. Only possible when the tumour hasn't invaded critical blood vessels or spread beyond the pancreas.
• Neoadjuvant chemotherapy: Increasingly, chemotherapy is given before surgery (particularly for borderline resectable tumours) to shrink the tumour and improve surgical outcomes. FOLFIRINOX and gemcitabine/nab-paclitaxel are common regimens.
• Adjuvant chemotherapy: Chemotherapy after surgery reduces recurrence risk. Modified FOLFIRINOX is the preferred regimen for fit patients.
• Palliative chemotherapy: For locally advanced or metastatic disease, chemotherapy can extend survival and improve quality of life. FOLFIRINOX and gemcitabine-based regimens are the mainstays.
• Biliary stenting: For pancreatic head tumours causing jaundice, a stent placed during ERCP relieves the obstruction before or instead of surgery.
• Surveillance for precursor lesions: For pancreatic cysts (particularly IPMNs) that don't meet criteria for surgery, regular MRI/MRCP surveillance at intervals determined by cyst size, features, and guidelines (typically annually for worrisome features, less frequently for low-risk cysts).

Related Articles

• MRI for Liver Cancer (HCC)